Afrezza Safety and Pharmacokinetics Study in Pediatric Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 28, 2017

Primary Completion Date

March 17, 2020

Study Completion Date

June 25, 2020

Conditions
Type 1 Diabetes Mellitus
Interventions
BIOLOGICAL

Afrezza

"Pharmaceutical form: powder~Route of administration: inhalation"

Trial Locations (13)

19104

Children's Hospital of Philadelphia, Philadelphia

21229

Barry J. Reiner, MD, LLC, Baltimore

30318

Atlanta Diabetes Associates, Atlanta

Van Meter Pediatric Endocrinology, P.C., Atlanta

30322

Emory University Children's Center, Atlanta

32610

University of Florida, Gainesville

33612

USF Diabetes Center, Tampa

38105

Le Bonheur Children's Hospital, Memphis

46202

Indiana University, Riley Hospital for Children, Indianapolis

80045

Barbara Davis Center for Childhood Diabetes, Aurora

89113

Diabetes, Obesity, Cardiovascular Clinical Specialists (DOCS), Las Vegas

90027

Children's Hospital Los Angeles, Los Angeles

06510

Yale University Hospital, New Haven

Sponsors
All Listed Sponsors
lead

Mannkind Corporation

INDUSTRY